Skip to main content
Wanbury Limited logo

Wanbury Limited — Investor Relations & Filings

Ticker · WANBURY ISIN · INE107F01022 LEI · 335800QB384KGMBID276 BSE.NS Manufacturing
Open in API
Filings indexed 914 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country IN India
Listing BSE.NS WANBURY

About Wanbury Limited

https://www.wanbury.com

Wanbury Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization maintains a significant global presence, particularly as a leading producer of Metformin. Its product portfolio spans diverse therapeutic areas, including gynecology, orthopedics, hematinics, and anti-diabetics. The company operates manufacturing facilities compliant with international regulatory standards, including the USFDA. Wanbury focuses on providing medicinal solutions through integrated research and development capabilities and large-scale production infrastructure, serving both domestic and international markets with a range of specialty products.

Recent filings

Filing Released Lang Actions
Press Release on Q4 & Year ended FY 2026 for Audited Financial Results
Regulatory Filings
2026-06-02 English
Press Release
Regulatory Filings
2026-06-02 English
Outcome of the Board Meeting held on 29.05.2026
Audit Report / Information Classification · 90% confidence The document is a statutory SEBI LODR disclosure containing the Board’s approval of audited financial results, the auditors’ unmodified opinion, the full Independent Auditors’ Report, and the audited P&L/OCI tables for the year ended March 31, 2026. It is not a full annual report (10-K), nor merely an earnings highlight or report publication announcement. Instead, it is a standalone audit report and the associated audited financial results. This matches the Audit Report / Information category (AR). FY 2026
2026-05-29 English
Outcome of the Board Meeting held on 29.05.2026
Regulatory Filings Classification · 85% confidence The document is a SEBI (LODR) compliance filing sent to BSE/NSE notifying the outcome of the Board meeting, enclosing the Audited Financial Results for the quarter and year ended March 31, 2026, plus the unmodified Auditor’s Report. It is not a full annual report (10-K), nor an investor presentation or proxy, nor simply a press highlight—it is a regulatory announcement of audited results under Indian listing rules. It therefore falls under the general “Regulatory Filings” category.
2026-05-29 English
Outcome of Board Meeting
Audit Report / Information Classification · 85% confidence The document is a regulatory filing under SEBI (LODR) consisting of the Board’s outcome letter approving the audited financial results for the quarter/year ended 31 March 2026, the unmodified auditor’s declaration, the full Independent Auditor’s Report by Kapoor & Parekh Associates, and the Statement of Audited Financial Results. It is not a full annual report, nor merely an earnings summary, but principally the auditor’s report and audit‐related disclosures. This matches the “Audit Report / Information” category. FY 2026
2026-05-29 English
The Board Meeting to be held on 14/05/2026 has been revised to 29/05/2026 The Board Meeting to be held on 14/05/2026 has been revised to 29/05/2026
Regulatory Filings Classification · 76% confidence The document is a notice to stock exchanges under SEBI Listing Regulations informing about the rescheduling of a Board Meeting to approve audited financial results. It does not contain the financial results themselves, nor is it a proxy statement or a management change announcement. It is a routine regulatory compliance filing to the exchanges. Therefore, it falls under Regulatory Filings (RNS).
2026-05-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.